Ignite Creation Date:
2024-05-06 @ 2:01 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04191187
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-03
First Post:
2019-12-06
Brief Title:
Reduced Intensity FluMelTBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Reduced-Intensity Fludarabine Melphalan and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells Haplo-HCT For Patients With Hematologic Malignancies
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single arm phase II trial of HLA-haploidentical related hematopoietic cells transplant Haplo-HCT using reduced intensity conditioning fludarabine and melphalan and total body irradiation Peripheral blood is the donor graft source This study is designed to estimate disease-free survival DFS at 18 months post-transplant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None